Wei Y, et al. - Researchers examined how the nucleos(t)ide analog (NA) use influences the prognosis of patients with HBV-related small hepatocellular carcinomas (HBV-SHCC). They conducted a retrospective study including 134 patients who had been treated with long-term NA before SHCC diagnosis as NA-experienced group, 43 patients received NA-naïve treatment after SHCC diagnosis as NA-naïve group, and 15 patients who did not receive NA treatment as untreated group. As per data gained, 1-year, 3-year, 5-year overall survival rate of HBV-SHCC patients in NA-experienced group were 90.27%, 90.69%, 65%, NA-naïve group were 70.81%, 73.95%, 47.39%, and untreated group were 54.96%, 40.44%, 47.39%, respectively. The longest survival time was evident for HBV-SHCC patients treated with adefovir dipivoxil (ADV) or LAM+ADV. Outcomes suggest that the treatment regimen may not change in SHCC patients treated with low drug resistance barrier drugs if they have gotten a virological response. Moreover, they recommend undertaking timely rescue therapy among HBV-SHCC patients who were suffering from virus break through even if their liver function was normal.